Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APS001F
- Development stage
- Phase 2
- Lead developer
- Anaeropharma Science
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies
- Administration
- Intravenous
01
Overview
APS001F is an investigational live biotherapeutic product developed by Anaeropharma Science. [1] It consists of a genetically-enhanced strain of the anaerobic bacterium *Bifidobacterium longum*, which is designed to selectively target and kill solid tumors. [1, 2] This novel therapy leverages the hypoxic (low-oxygen) environment characteristic of solid tumor cores, where the intravenously administered APS001F can selectively colonize and proliferate. [1] The bacterium is engineered to express the enzyme cytosine deaminase (CD). [1, 2, 4] This enzyme locally converts a systemically administered, non-toxic prodrug, flucytosine (5-FC), into the potent cytotoxic chemotherapy agent 5-fluorouracil (5-FU) directly at the tumor site. [1, 2, 4] This tumor-specific production of 5-FU aims to achieve high intratumoral concentrations of the anticancer agent while minimizing systemic toxicity associated with conventional chemotherapy. [1, 4]
- Other names
- CD-expressing bifidobacterium APS001F
02
Targets
CD (Cluster of Differentiation antigens)TS (Thymidylate synthase)
Beyond the preview
Go deeper on APS001F.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APS001F.